Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27765163 | 0.84 | HPGD (0.73) | POLBPKMALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL9879475 | 0.83 | POLB (0.71) | POLBPKMALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27787210 | 0.82 | POLB (0.70) | POLBALDH1A1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL27765446 | 0.82 | POLB (0.69) | POLBALDH1A1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL27765509 | 0.80 | POLB (0.66) | POLBALDH1A1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL27765148 | 0.79 | GPR84 (0.70) | POLBALDH1A1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL27787314 | 0.79 | POLB (0.65) | POLBPKMALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27787311 | 0.79 | KMT2A (0.67) | POLBPKMALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27787217 | 0.79 | HPGD (0.74) | POLBPKMALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5907132 | 0.78 | POLB (0.64) | POLBPKMALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620407-A2 | OXO-PYRIMIDINE COMPOUNDS | Idenix (Cayman) Limited (KY) | 2006-02-01 | — | — | EP | disclosed |
| US-20050014774-A1 | Oxo-pyrimidine compounds | STORER RICHARD (GB) | 2005-01-20 | — | — | US | disclosed |
| WO-2004096147-A2 | OXO-PYRIMIDINE COMPOUNDS | IDENIX (CAYMAN) LIMITED (KY) | 2004-11-11 | — | — | WO | disclosed |
| WO-1991018887-A1 | DIAMINOPYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014774-A1 | Oxo-pyrimidine compounds | TYMP, TYMS, HPRT1 | POLB 16/4885PKM 1689/4885ALDH1A1 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.